X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
plx4032 (7) 7
rg7204 (7) 7
index medicus (4) 4
melanoma (4) 4
braf inhibitor (3) 3
braf mutation (3) 3
cancer (3) 3
genetic-dependent therapy (3) 3
humans (3) 3
indoles - therapeutic use (3) 3
mutations (3) 3
proto-oncogene proteins b-raf - genetics (3) 3
sulfonamides - therapeutic use (3) 3
thyroid cancer (3) 3
vemurafenib (3) 3
article (2) 2
b-raf (2) 2
braf (2) 2
cell line, tumor (2) 2
cell proliferation - drug effects (2) 2
cells (2) 2
indoles - pharmacology (2) 2
melanoma - drug therapy (2) 2
melanoma - enzymology (2) 2
pathway (2) 2
proto-oncogene proteins b-raf - antagonists & inhibitors (2) 2
resistance (2) 2
ro5185426 (2) 2
sulfonamides - pharmacology (2) 2
therapy (2) 2
60 applied life sciences (1) 1
activation (1) 1
amino acid substitution (1) 1
amino acid substitution - genetics (1) 1
animals (1) 1
antineoplastic agents - adverse effects (1) 1
antineoplastic agents - therapeutic use (1) 1
bases (1) 1
biochemistry & molecular biology (1) 1
biophysics (1) 1
b‐raf (1) 1
cell biology (1) 1
cell proliferation (1) 1
clinical trials as topic (1) 1
clinical-implications (1) 1
dermatology (1) 1
disease-free survival (1) 1
dna mutational analysis (1) 1
drug evaluation, preclinical (1) 1
drug resistance, neoplasm - genetics (1) 1
drug therapy (1) 1
drug-resistance (1) 1
enzyme inhibitors - pharmacology (1) 1
enzyme inhibitors - therapeutic use (1) 1
erk (1) 1
gene (1) 1
genetic aspects (1) 1
growth (1) 1
health aspects (1) 1
indoles - adverse effects (1) 1
inhibition (1) 1
kinase (1) 1
kinase inhibitor (1) 1
mek (1) 1
melanoma - genetics (1) 1
melanoma - pathology (1) 1
melanoma metastatic (1) 1
melanomas (1) 1
metastatic (1) 1
metastatic melanoma (1) 1
mice (1) 1
models, biological (1) 1
mutants (1) 1
mutation (1) 1
oncology (1) 1
pathogenic role (1) 1
pharmacology & pharmacy (1) 1
phosphorylation (1) 1
plx4032 rg7204 (1) 1
progression (1) 1
proliferation (1) 1
protein kinase inhibitors - pharmacology (1) 1
protein kinase inhibitors - therapeutic use (1) 1
raf inhibitors (1) 1
randomized controlled trials as topic (1) 1
remission induction (1) 1
research (1) 1
sensitivity (1) 1
signal transduction - drug effects (1) 1
solid tumors (1) 1
sorafenib (1) 1
squamous-cell carcinomas (1) 1
sulfonamides - adverse effects (1) 1
survival (1) 1
therapies (1) 1
thyroid (1) 1
thyroid neoplasms - drug therapy (1) 1
thyroid neoplasms - genetics (1) 1
trials (1) 1
tumor-growth (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Pharmacotherapy, ISSN 1060-0280, 11/2011, Volume 45, Issue 11, pp. 1399 - 1405
Journal Article
Future Oncology, ISSN 1479-6694, 05/2012, Volume 8, Issue 5, pp. 509 - 523
Vemurafenib is a potent inhibitor of the mutated BRAF kinase. Phase I and II CIinical trials of vemurafenib showed response rates of more than 50% in patients... 
zelboraf | metastatic | PLX4032 | vemurafenib | melanoma | BRAF | RG7204 | SURVIVAL | CELLS | ACTIVATION | vemurafenib zelboraf | DRUG-RESISTANCE | CANCER | PLX4032 RG7204 | melanoma metastatic | METASTATIC MELANOMA | ONCOLOGY | PATHWAY | GROWTH | B-RAF | MUTATIONS
Journal Article
Journal Article
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ISSN 0006-291X, 01/2011, Volume 404, Issue 4, pp. 958 - 962
Aberrant signaling of the Ras-Raf-MEK-ERK (MAP kinase) pathway driven by the mutant kinase BRAF(V600E), as a result of the BRAF(T1799A) mutation, plays a... 
BASES | PLX4032 | BIOCHEMISTRY & MOLECULAR BIOLOGY | KINASE | BRAF inhibitor | PATHOGENIC ROLE | BRAF mutation | Genetic-dependent therapy | Thyroid cancer | BIOPHYSICS | CLINICAL-IMPLICATIONS | RAF INHIBITORS | RG7204 | MUTANTS | INHIBITION | THERAPY | PHOSPHORYLATION | SENSITIVITY | THYROID | CELL PROLIFERATION | MELANOMAS | MUTATIONS | 60 APPLIED LIFE SCIENCES
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 2011, Volume 404, Issue 4, pp. 958 - 962
► Exciting therapeutic potential has been recently reported for the BRAF inhibitor PLX4032 in melanoma. ► We tested the effects of PLX4032 on the growth of... 
Genetic-dependent therapy | Thyroid cancer | PLX4032 | BRAF inhibitor | RG7204 | BRAF mutation
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.